RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Budget Impact of Adding Delayed-Release Dimethyl Fumarate to the Formulary for the Treatment of Relapsing Forms of Multiple Sclerosis
Mauskopf, J., Fay, M., Iyer, R., & Livingston, T. (2014). Budget Impact of Adding Delayed-Release Dimethyl Fumarate to the Formulary for the Treatment of Relapsing Forms of Multiple Sclerosis. Value in Health, 17(3), A58-A58.
